编者按：最近，在有关慢性乙型肝炎（CHB）功能性治愈的学术讨论中，发现人们对于循环血中乙型肝炎病毒（HBV）的血清学和病毒学标志物的认识存在一定的分歧。为此，本刊特邀请北京大学医学部庄辉院士分享了对此问题的看法。现将其内容简要整理如下，供广大读者学习 ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for ...

老一代抗HBV感染药物拉米夫定、替比夫定因抑制HBV DNA能力较弱、耐药屏障过低、易耐药等因素影响后续治疗及患者预后，目前已逐渐淡出“江湖”，基本处于“退役”状态，临床亟需更多优质高效、母婴安全的新一代药物。

Gabow, I.A. and Mohamed, A.A. (2025) Assessment of Knowledge, Attitude and Vaccination Status of Hepatitis B Infection among Medical University Students in Mogadishu-Somalia. Journal of Biosciences ...

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), retaining the price target of ...

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

Several hospitals and nursing homes, especially in the private sector, are reportedly facing a shortage of hepatitis B ...

Hepatitis is an inflammation of the liver, usually caused by a viral infection, specifically the Hepatitis A, B, C, D, or E ...

Discover a study that highlights that both the 2-dose and 3-dose HepB-CpG regimens provide better seroprotection compared to ...

Shortage of hepatitis B vaccine in Kerala's private hospitals poses risks, highlighting importance of vaccination for prevention.